Meta-analysis of 3,512 patients: obicetrapib added to ezetimibe nearly doubles LDL-C lowering seen with obicetrapib alone, but adds nothing to statins (Cardiol Rev 2026)

Original title: Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized Controlled Trials

Cardiol Rev · 29 June 2026 · 6

Jha M, Chahodiya D, Matawala K, Kharal M, Thaker L, Maheta D, Jain H, Daga P, Agarwal S, Frishman WH, Aronow WS

A meta-analysis of randomised controlled trials of obicetrapib, alone and as add-on therapy, pooling 3,512 patients through September 2025. Obicetrapib alone reduced LDL-C by a mean difference of 37.45 mg/dL (95% CI, 31.15 to 43.76), non-HDL cholesterol by 32.04 mg/dL and apoB by 24.71 mg/dL, while raising HDL cholesterol by 147.98 mg/dL and apolipoprotein A1 by 55.54 mg/dL. Added to ezetimibe, obicetrapib produced a larger LDL-C reduction of 51.99 mg/dL and non-HDL reduction of 50.32 mg/dL, but no significant incremental effect when combined with statins. All figures are pooled from existing randomised trials rather than new data.

Original abstract

Obicetrapib is a cholesteryl ester transfer protein inhibitor that demonstrated reductions in atherogenic lipoproteins. We systematically searched PubMed, Scopus, and Clinicaltrials.gov for relevant randomized controlled trials from inception until September 2, 2025 to evaluate the efficacy and safety outcomes of obicetrapib as a standalone and add-on therapy. The mean difference (MD) with 95% confidence intervals (CI) was pooled using a random effects model. A total of 3512 patients were included. Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001], non-high-density lipoprotein (HDL) cholesterol [MD, -32.04 (95% CI, -38.49 to -25.60), P < 0.001], apolipoprotein B [MD, -24.71 (95% CI, -30.79 to -18.63), P < 0.001] and apolipoprotein A [MD, -39.10 (95% CI, -45.35 to -32.85), P < 0.001]. It significantly increased total cholesterol [MD, +10.41 (95% CI, 3.68-17.15), P < 0.001], HDL cholesterol [MD, +147.98 (95% CI, 129.23-166.54), P < 0.001], apolipoprotein A1 [MD, 55.54 (95% CI, 43.37-67.71)], and apolipoprotein E [MD, 53.24 (95% CI, 39.04-67.44), P < 0.001]. As an add-on therapy to ezetimibe, obicetrapib yielded greater reduction in low-density lipoprotein [MD, -51.99 (95% CI, -61.61 to -42.37), P < 0.001] and non-HDL [MD, -50.32 (-55.42 to -45.21), P < 0.001]. No significant effects were observed when combined with statins.

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.